Cannabis Health Symposium: London 2026 returns to London for a full day of evidence-led education focused on the evolving UK medical cannabis sector.

The symposium brings together healthcare professionals, clinicians, industry professionals and patient advocates to explore key developments across medical cannabis policy, regulation, patient access and clinical practice. Pasted text

The programme features 18 sessions, including six panel debates, with discussions covering regulatory requirements for unlicensed cannabis-based medicines, NHS pathways, clinical governance, workplace considerations, police guidance, harmonisation of cannabis-based medicines and patient safety. Pasted text

The afternoon programme moves into science and clinical practice, examining medical cannabis in mental health care, neurological disorders and neurodiversity, real-world evidence versus randomised controlled trials, women’s health, pain treatment and patient experiences. Pasted text

A dedicated workshop stage will run alongside the main programme, addressing topics including patient safety and the illicit market, patient discrimination, and the role of social science in improving medical cannabis patient outcomes. Pasted text

The symposium is intended to provide practical, clinically relevant insight for professionals working with or interested in cannabis-based medicines and the UK’s developing medical cannabis landscape.

Who Should Attend?

The official source identifies the target audience as: Pasted text

• Healthcare professionals
• Clinicians
• Industry professionals
• Patient advocates
• Medical cannabis practitioners
• Researchers
• Prescribers
• Healthcare providers
• Professionals involved in medical cannabis regulation and access

Programme Highlights

Morning — Policy, Regulation & Access

08:30 — Doors open, registration & networking coffee

09:20 — Opening remarks & welcome

09:25 — Headline partner keynote

09:40 — Regulating unlicensed cannabis-based medicines: latest guidance and developments

10:00 — Cannabis-based medicines and NHS pathways

10:20 — Building a safe, effective and compliant medical cannabis service

11:00 — Medical cannabis in the workplace: safety, compliance and employee rights

11:30 — Medical cannabis police guidance: understanding rights and responsibilities

12:00 — Setting the Standard: How Harmonisation Turns CBMs Into Trusted Care

12:30 — Session to be announced

13:00 — Lunch & networking

These sessions and times are directly supported by the supplied programme. Pasted text

Afternoon — Science & Clinical Practice

14:00 — Managing risk and maximising benefit in mental health care

14:40 — Cannabis for Neurological Disorders and Neurodiversity: Fact or Fiction?

15:00 — RCT vs RWE: is it time to look beyond the placebo-controlled trial?

15:30 — Addressing unmet needs in women’s health

15:50 — Medical Cannabis and Pain Treatment: What Real World Evidence Tells Us

16:10 — Patient round-table

17:00 — Close

Featured Speakers

The source lists:

• Professor David Nutt — Professor of Neuropsychopharmacology, Imperial College London, Drug Science
• Alex Fraser — Founder & Managing Director, Patient Protect
• Richard List — National Secretary and CDLO, Association of Police Controlled Drug Liaison Officers
• Shanna Marrinan — Director of Research, 4C Labs
• Professor Kim Wolff — Director of King’s Forensics, King’s College London
• Ana Serrato — Chair, Cannabis Human Health Subcommittee; Chairwoman, EUMCA, ASTM International
• Dr Anna Waldstein — Senior Lecturer in Medical Anthropology, University of Kent
• David Tang — CEO & Founder, CannPrescribe
• Dr Simon Tordoff — Consultant in Pain Management, CB1 Medical
• Sarah Sinclair — Editor, Cannabis Health

Included Benefit

12 months’ free Medical Cannabis Clinicians Society (MCCS) membership — worth up to £120.